Patients and methods
Two groups of patients were retrospectively collected from our database. Group 1: 18 patients (14 males, 4 females, mean age 68±15 years) with a single sirolimus-eluting stent on mid-LAD (follow-up 15±8 months), and Group 2: 15 patients (10 males, 5 females, mean age 69.8±15.4 years) with a single Titan2 stent (nitric oxide stratified) on mid-LAD. All these patients underwent new coronary angiography and optical coherence tomography (OCT).
Patients and methods
Two groups of patients were retrospectively collected from our database. Group 1: 18 patients (14 males, 4 females, mean age 68±15 years) with a single sirolimus-eluting stent on mid-LAD (follow-up 15±8 months), and Group 2: 15 patients (10 males, 5 females, mean age 69.8±15.4 years) with a single Titan2 stent (nitric oxide stratified) on mid-LAD. All these patients underwent new coronary angiography and optical coherence tomography (OCT).
Results
Clinical data: Follow-up was 1.8±0.6 years (range 5–26 months) in Group 1 and 1.7±0.9 years (range 5–28 months) in Group 2. No significant difference was encountered between the two groups of patients for the usual coronary risk factors. No patient had had any episode of stent thrombosis in either Group 1 or Group 2. Eleven patients in Group 1 were on double antiplatelet oral therapy (aspirin and clopidogrel), while all patients in Group 1 had clopidogrel interrupted after 1 month. Angiographic data: No significant difference existed between Group 1 and Group 2 either in terms of stent initial diameter and length (3.2±0.4 vs. 3.1±0.5 and 23±12 vs. 23±8 mm, respectively) or in the type of coronary stenosis (Group 1: B2 in 50%, C in 50%; Group 2: B1 in 10%, B2 in 40%, and C in 50%). The initial luminal gain was not different in Groups 1 and 2 (2.2±0.3 vs. 2.4±0.5 mm), while late loss was 0.9±0.8 mm in Group 1 vs. 0.1±0.05 mm in Group 2 ( P <.001). No patients showed binary restenosis in Group 1, while one patient (6.6%) had a 60% in-stent restenosis in Group 2. OCT data: Neointimal thickness was significantly less in Group 1 (175±12 vs. 1040±279 μm, P <.001). Incomplete apposition was not detected in any patients in either Group 1 or Group 2. Only 64% (on a total of 3568) of struts were covered in Group 1 vs. 99% (on a total of 3875) in Group 2 ( P <.001). Furthermore, type 1, 2, and 3 coverage were significantly more frequent in Group 1 (86±12% vs. 12±8%, P <.001). Nonocclusive stratified thrombosis was detected only in four patients (22.2%), all in Group 1 ( P <.01). All these patients were on double antiplatelet therapy. In these patients, strut coverage was only 32%.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
